Mitchell E. Levinson - 17 Apr 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Strategy Officer, Director
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol
PLSE
Transactions as of
17 Apr 2023
Net transactions value
$0
Form type
4
Filing time
09 May 2023, 21:46:31 UTC
Previous filing
11 Oct 2022
Next filing
06 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award +17,700 17,700 08 May 2023 Common Stock 17,700 $8.02 Direct F1, F2
transaction PLSE Stock Option (right to buy) Award +2,000 2,000 17 Apr 2023 Common Stock 2,000 $5.81 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on May 8, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to performance-based vesting criteria. 4,425 shares will vest in equal annual installments over the following four years, subject to achievement of the vesting criteria and the reporting person's continued service through each vesting date.
F2 Not applicable.